Session » Systemic Sclerosis & Related Disorders – Clinical Poster I

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 731

A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)

9:00AM-11:00AM: Abstract Number: 725

Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers

9:00AM-11:00AM: Abstract Number: 720

Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 724

Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review

9:00AM-11:00AM: Abstract Number: 714

Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry

9:00AM-11:00AM: Abstract Number: 717

Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities

9:00AM-11:00AM: Abstract Number: 718

Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions

9:00AM-11:00AM: Abstract Number: 723

Diagnosis of Systemic Sclerosis: How and When

9:00AM-11:00AM: Abstract Number: 726

Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 719

Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth

9:00AM-11:00AM: Abstract Number: 739

Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?

9:00AM-11:00AM: Abstract Number: 730

Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma

9:00AM-11:00AM: Abstract Number: 715

Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 708

Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences

9:00AM-11:00AM: Abstract Number: 716

Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 729

Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 727

Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 728

Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity

9:00AM-11:00AM: Abstract Number: 736

Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders

9:00AM-11:00AM: Abstract Number: 710

Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 734

Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 732

Risk of Heart Valve Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 740

Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 712

Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics

9:00AM-11:00AM: Abstract Number: 707

Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts

9:00AM-11:00AM: Abstract Number: 709

Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 738

Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis

9:00AM-11:00AM: Abstract Number: 722

The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 737

The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 735

The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 711

Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints

9:00AM-11:00AM: Abstract Number: 721

Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 733

Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].